HomeREGULATORY
REGULATORY

Keytruda Earns Lymphoma Nod, Novo’s Norditropin Label Expanded
(Dec.1.2017)

MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) was approved for an additional indication of recurrent or refractory classical Hodgkin’s lymphoma (cHL) on November 30, which marks its third indication in Japan following melanoma and non-small cell lung cancer ...
(LOG IN FOR FULL STORY)